secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001558370-25-011311
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood Therapeutics Q2 net loss $3.8M; Halneuron Phase 2b interim data on track for Q4 2025
--------------------------------------------------------------------------------

- Enrolled 52 patients in Halneuron Phase 2b CINP trial; low discontinuation rate of 5.8% due to adverse events.
- R&D expenses $2.5M (up from $0.3M) driven by clinical trial costs; G&A $1.3M (up from $0.7M).
- Net loss $3.8M ($1.99 per share) vs $1.0M ($1.15) in Q2 2024; no revenue reported.
- Cash $13.4M expected to fund operations through Q1 2026; Halneuron fast-tracked by FDA.
- IMC-1 (fibromyalgia) ready for Phase 3; IMC-2 (Long-COVID) paused due to government funding uncertainty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837025011311/0001558370-25-011311-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837025011311/dwtx-20250813x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011311

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer